P. Alves

发表

Reverse immunology approach for the identification of CD8 T‐cell‐defined antigens: Advantages and hurdles

P. Romero, S. Viatte, P. Alves, 2006, Immunology and cell biology.

Identification of HER‐2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors

F. Lemonnier, S. Chouaib, L. Nadler, 2001, European journal of immunology.

Lymphocyte Proliferation T + and Antigen-Experienced CD 8 Distinct Mechanisms Control Human Naive Romero and

P. Romero, N. Rufer, M. Migliaccio, 2006 .

Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation1

P. Romero, N. Rufer, M. Migliaccio, 2006, The Journal of Immunology.

Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002, The Journal of Immunology.

In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse

P. Opolon, F. Lemonnier, R. Glück, 2003, British Journal of Cancer.

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

D. Speiser, P. Romero, O. Michielin, 2005, Cancer treatment and research.

pH-Triggered Microparticles for Peptide Vaccination

Daniel G. Anderson, R. Langer, W. Haining, 2004, The Journal of Immunology.

Prediction of Cross-Recognition of Peptide-HLA A2 by Melan-A-Specific Cytotoxic T Lymphocytes Using Three-Dimensional Quantitative Structure-Activity Relationships

D. Speiser, P. Baumgaertner, P. Romero, 2013, PloS one.

Lentivector immunization induces tumor antigen‐specific B and T cell responses in vivo

D. Valmori, S. Colombetti, F. Lévy, 2008, European journal of immunology.

Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors 1

D. Speiser, P. Romero, N. Rufer, 2009, The Journal of Immunology.

Induction of multiple CD 8 + T cell responses against the inducible Hsp 70 employing an Hsp 70 oligoepitope peptide

F. Lemonnier, I. Miconnet, J. Abastado, 2022 .

High-throughput screening of human tumor-antigen specific CD4 T cells, 1 including neo-antigen reactive T cells

W. Reith, D. Speiser, P. Baumgaertner, 2019 .

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

F. Lemonnier, I. Miconnet, S. Chouaib, 2003, Cancer research.

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer

D. Speiser, P. Romero, S. Viatte, 2007, Cancer Immunology, Immunotherapy.

Broad-Spectrum Tumor Immunotherapy-A 12 Tumor Antigens : Implication in a MAGE-A 1 ,-A 2 ,-A 3 ,-A 4 ,-A 6 ,-A 10 , and HLA-A * 0201-Restricted Epitope Shared by Generation of CTL Recognizing an

F. Lemonnier, S. Chouaib, S. Graff-Dubois, 2002 .

Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.

C. V. Jongeneel, Brian J. Stevenson, D. Speiser, 2008, Cancer immunity.

STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

J. Soria, F. Lemonnier, I. Miconnet, 2006, Cancer Immunology, Immunotherapy.

HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1

F. Lemonnier, S. Chouaib, L. Nadler, 2002, The Journal of Immunology.

Novel Targets for Broad Spectrum Tumor and hTERT Cryptic Epitopes as neu HER-2 /

F. Lemonnier, S. Chouaib, L. Nadler, 2002 .

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

P. Opolon, J. Davoust, F. Lemonnier, 2004, The Journal of clinical investigation.

Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients

D. Speiser, P. Romero, O. Michielin, 2007, Cancer Immunology, Immunotherapy.

TRIAL A phase I / II trial of the safety and clinical activity of a HER 2-protein based immunotherapeutic for treating women with HER 2-positive metastatic breast cancer

A. Callegaro, G. Curigliano, M. Campone, 2016 .

Recombinant protein vaccination for antigen-specific cancer immunotherapy

V. Brichard, P. Alves, 2011 .

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA‐A*0201‐restricted epitopes

F. Lemonnier, I. Miconnet, J. Abastado, 2004, International journal of cancer.

pH-Triggered Microparticles for Peptide Vaccination1

Daniel G. Anderson, R. Langer, W. Haining, 2004, The Journal of Immunology.